Characterization of the Early Cellular Immune Response Induced by HPV Vaccines

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 4

PMID 35924247

Authors

Hella Pasmans

Magdalena A Berkowska

Annieck M Diks

Bas de Mooij

Rick J Groenland

Lia de Rond

M Alina Nicolaie

Sjoerd H van der Burg

Jacques J M van Dongen

Fiona R M van der Klis

Anne-Marie Buisman

Affiliations

Soon will be listed here.

Abstract

Introduction: Current human papillomavirus (HPV) vaccines consist of virus-like particles (VLPs) which are based on the L1 protein, but they are produced by different expression systems and use different adjuvants. We performed in-depth immunophenotyping of multiple innate and adaptive immune cells after vaccination with bivalent versus nonavalent HPV vaccines.

Method: Twenty pre-menopausal HPV-seronegative women were enrolled and randomized to receive three-doses of either the bivalent or the nonavalent HPV vaccine. Blood samples were collected at multiple time points from baseline up to 7 months after first vaccination. Four extensive EuroFlow flow cytometry antibody panels were used to monitor various immune cell subsets. Additionally, HPV-specific memory B- and T cells were determined by ELISPOT and HPV-specific antibody levels were measured by a VLP-based multiplex immunoassay.

Results: In both cohorts, the numbers of plasma cells expanded in the first week after both primary and tertiary vaccination. HPV16 and HPV18-specific antibody levels and memory B and T-cell responses were higher in the bivalent than in the nonavalent vaccinees one month post third vaccination. For HPV31 and HPV45-specific antibody levels this pattern was reversed. Monocytes showed an expansion one day after vaccination in both cohorts but were significantly higher in the bivalent vaccine cohort. Large heterogeneity in responses of the other cell subsets was observed between donors.

Conclusion: This pilot study showed a consistent response of monocytes and plasma cells after vaccination and a considerable variation in other circulating immune cells in both types of HPV vaccines between donors.

Citing Articles

Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine.

Quang C, Anderson J, Russell F, Reyburn R, Ratu T, Tuivaga E Nat Commun. 2025; 16(1):2130.

PMID: 40032823 PMC: 11876628. DOI: 10.1038/s41467-025-57443-z.

The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV).

Movahed F, Darzi S, Mahdavi P, Mahdi M, Allela O, Sameer H Virol J. 2024; 21(1):124.

PMID: 38822328 PMC: 11143593. DOI: 10.1186/s12985-024-02397-9.

Immune response following a two-dose schedule of bivalent HPV vaccination among girls and boys.

Middeldorp M, Duijster J, van de Kassteele J, van der Klis F, de Melker H Front Immunol. 2024; 15:1327770.

PMID: 38343547 PMC: 10853341. DOI: 10.3389/fimmu.2024.1327770.

Performance of spectral flow cytometry and mass cytometry for the study of innate myeloid cell populations.

van der Pan K, Khatri I, de Jager A, Louis A, Kassem S, Naber B Front Immunol. 2023; 14:1191992.

PMID: 37275858 PMC: 10235610. DOI: 10.3389/fimmu.2023.1191992.

References

Giannini S, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F . Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24(33-34):5937-49. DOI: 10.1016/j.vaccine.2006.06.005. View

Ruiz W, McClements W, Jansen K, Esser M . Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines. 2005; 3(1):2. PMC: 1097753. DOI: 10.1186/1476-8518-3-2. View

Vidarsson G, Dekkers G, Rispens T . IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014; 5:520. PMC: 4202688. DOI: 10.3389/fimmu.2014.00520. View

Schiller J, Lowy D . Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol. 2012; 10(10):681-92. PMC: 6309166. DOI: 10.1038/nrmicro2872. View

Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart D . Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116(16):e74-80. DOI: 10.1182/blood-2010-02-258558. View

Botafogo V, Perez-Andres M, Jara-Acevedo M, Barcena P, Grigore G, Hernandez-Delgado A . Age Distribution of Multiple Functionally Relevant Subsets of CD4+ T Cells in Human Blood Using a Standardized and Validated 14-Color EuroFlow Immune Monitoring Tube. Front Immunol. 2020; 11:166. PMC: 7056740. DOI: 10.3389/fimmu.2020.00166. View

Stone K, Prussin C, Metcalfe D . IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S73-80. PMC: 2847274. DOI: 10.1016/j.jaci.2009.11.017. View

Pinto L, Edwards J, Castle P, Harro C, Lowy D, Schiller J . Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis. 2003; 188(2):327-38. DOI: 10.1086/376505. View

Tiberio L, Fletcher L, Eldridge J, Duncan D . Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine. 2004; 22(11-12):1515-23. DOI: 10.1016/j.vaccine.2003.10.019. View

10.

Coffman R, Sher A, Seder R . Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33(4):492-503. PMC: 3420356. DOI: 10.1016/j.immuni.2010.10.002. View

11.

Mariz F, Bender N, Anantharaman D, Basu P, Bhatla N, Pillai M . Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020; 5(1):14. PMC: 7021830. DOI: 10.1038/s41541-020-0165-x. View

12.

Einstein M, Baron M, Levin M, Chatterjee A, Fox B, Scholar S . Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin. 2011; 7(12):1359-73. PMC: 3338933. DOI: 10.4161/hv.7.12.18282. View

13.

Scherpenisse M, Schepp R, Mollers M, Meijer C, Berbers G, van der Klis F . Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013; 8(9):e74797. PMC: 3776846. DOI: 10.1371/journal.pone.0074797. View

14.

Ma C, Deenick E . Human T follicular helper (Tfh) cells and disease. Immunol Cell Biol. 2013; 92(1):64-71. DOI: 10.1038/icb.2013.55. View

15.

Scherpenisse M, Mollers M, Schepp R, Boot H, de Melker H, Meijer C . Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine. 2012; 30(47):6686-93. DOI: 10.1016/j.vaccine.2012.08.068. View

16.

Doedee A, Kannegieter N, Ozturk K, van Loveren H, Janssen R, Buisman A . Higher numbers of memory B-cells and Th2-cytokine skewing in high responders to hepatitis B vaccination. Vaccine. 2016; 34(19):2281-9. DOI: 10.1016/j.vaccine.2015.12.027. View

17.

Schiller J, Lowy D . Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018; 36(32 Pt A):4768-4773. PMC: 6035892. DOI: 10.1016/j.vaccine.2017.12.079. View

18.

Diks A, Versteegen P, Teodosio C, Groenland R, de Mooij B, Buisman A . Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination. Vaccines (Basel). 2022; 10(2). PMC: 8878388. DOI: 10.3390/vaccines10020136. View

19.

Einstein M, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F . Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009; 5(10):705-19. DOI: 10.4161/hv.5.10.9518. View

20.

Blanco E, Perez-Andres M, Arriba-Mendez S, Contreras-Sanfeliciano T, Criado I, Pelak O . Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J Allergy Clin Immunol. 2018; 141(6):2208-2219.e16. DOI: 10.1016/j.jaci.2018.02.017. View